Candela's Vbeam Receives FDA Clearance for Treatment of Periorbital Wrinkles.

Business Editors and Health/Medical Writers

WAYLAND, Mass.--(BW HealthWire)--Feb. 12, 2002

New application hailed by physicians as a "quantum jump in

technology"

Candela Corporation (NASDQ: CLZR) today announced that it has received FDA clearance from the U.S. Food and Drug Administration to market the Vbeam(R) pulsed dye laser for treatment of periorbital wrinkles. Candela will demonstrate this important new application for its Vbeam at the annual meeting of the American Academy of Dermatology on February 22 in New Orleans.

Candela's Vbeam is the acknowledged leader in the treatment of a broad base of vascular lesions. Richard E. Fitzpatrick, M.D., of Dermatology Associates of San Diego, CA, confirmed the Vbeam's position, stating, "The Vbeam combines the best wavelength with the best pulsewidth for treatment of cutaneous vessels and delivers adequate fluence with protection of the epidermis. It is clearly the best vascular laser I have seen." The FDA's clearance of the Vbeam for the treatment of periorbital wrinkles expands the laser's utility into aesthetics, the fastest growing light-based application. In addition to the new marketing indication, Candela has also created an upgrade package for existing Vbeam users, including multiple improvements to both hardware and software.

"We're excited that this new clearance validates the anecdotal feedback we've been receiving virtually since the Vbeam's introduction two years ago - namely, that this laser has exceptional utility in the treatment of periorbital wrinkles," said Gerard E. Puorro, President and CEO of Candela. "The FDA clearance can increase physicians' confidence in the Vbeam not only as an important laser for the medical treatment of vascular lesions, but as a laser for periorbital wrinkle reduction. We feel this new clearance confirms the Vbeam's versatility and utility as a staple in the physician's office."

David E. Bank, M.D., of the Center for Dermatology, Cosmetic and Laser Surgery in Mt. Kisco, NY, expressed enthusiasm for the Vbeam as a landmark tool for the treatment of periorbital wrinkles, saying, "The Vbeam has put the treatment of periorbital wrinkles in the `lunchtime treatment' category which represents a quantum jump in technology."

Information, demonstrations and research on the Vbeam for periorbital wrinkles will be available to physicians and press at Candela's Booth #2321.

About Candela: Candela Corporation develops, manufactures, and distributes innovative clinical solutions that enable physicians, surgeons, and personal care practitioners to treat selected cosmetic and medical conditions using lasers, aesthetic laser systems, and other advanced technologies. Founded near Boston in 1970, the company markets and services its products in over 55 countries from offices in the United States, Europe, Japan and Asia. Candela established the aesthetic laser market 12 years ago, and currently has an installed base of over 5,000 lasers worldwide. Candela is an Equal Opportunity and Affirmative Action Employer, M/F/H/V. Visit Candela on the Web at www.clzr.com.

Safe Harbor Statement: Except for the historical information contained herein, this news release contains forward-looking statements that constitute Candela's current intentions, hopes, beliefs, expectations or predictions of the future, which are therefore inherently subject to risks and uncertainties. Candela's actual results could differ materially from those anticipated in Candela's forward-looking statements based on various factors, including without limitation: cancellation or deferral of customer orders, total dependence on a small number of strategic distribution relationships, difficulties in the timely development and market acceptance of new products, market developments that vary from the current public expectations concerning the growth of the laser industry, increased competitive pressures, or changes in economic conditions. Further information on factors that could affect Candela's performance is included in Candela's periodic reports filed with the SEC, including but not limited to, Candela's Annual Report on Form 10-K (or any amendment thereto) for the year ended June 30, 2001, and subsequent Quarterly Reports on Form 10-Q. Candela cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Candela expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Candela's expectations or any change in events, conditions or circumstance on which any such statement is based.